Oncogen Pharma Malaysia is a wholly-owned subsidiary company of Scitech Limited. In 2006, Scitech Limited expanded its business in India by establishing a Research & Development Centre and a Manufacturing Plant with a focus on producing Non-Oncology Active Pharmaceutical Ingredients (API) and raw materials for pharmaceutical drugs manufacturers.

After 7 years of its establishment, Scitech Limited has successfully obtained US FDA approval for its facilities in India, has registered more than 100 patents, and has commercialized 84 products which are being exported to regulated and semi-regulated markets all over the world. Furthermore, Scitech Limited has recruited from all over the world the best talent, trained and retained the top innovators in the API field.

Scitech Limited has the policy of continuously re-investing in the state of the art technology, systems and people. This policy has paid multiple dividends not only in the financial terms, but also in terms of building brands, strong customer base and intellectual property. This policy has also allowed Scitech Limited to harvest resilient human capital as well as to produce the niche and complex APIs.

Being established in 2015, Oncogen Pharma is a foray of Scitech Limited into a new growth segment - Research & Development, Manufacturing and Commercialization of Oncology API and Formulation. As a subsidiary company of Scitech Limited, Oncogen Pharma has the vision to serve the same policy where we seek to supply high quality Oncology products at competitive prices while complying with all the stringent regulatory requirements. For this purpose, seeking US FDA approval for our Oncology products is one of our top priorities.